Aspiro Therapeutics Establishes Advisory Board to Support Development of Lead Therapy
Tucson, Arizona / June 11, 2025 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced the strategic addition of two new advisors: Matt Britz and Dr. Anne Dixon. Their combined leadership in respiratory science, clinical development, and biotech company building will significantly support Aspiro’s […]
Aspiro Therapeutics Selected to Present at 2025 BIO Startup Stadium
Tucson, Arizona / May 28, 2025 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced its selection to present at the BIO 2025 Startup Stadium, part of the BIO International Convention taking place June 17 to 20 in Boston, Massachusetts. Aspiro will present its […]
Aspiro Therapeutics Selected to Present at 2025 Respiratory Innovation Summit
Tucson, Arizona / April 17, 2025 — Aspiro Therapeutics, a biopharmaceutical company dedicated to pioneering the development of groundbreaking treatments for obstructive lung diseases, announced today that it has been selected as a Showcase Company at the 2025 Respiratory Innovation Summit (RIS), hosted by the American Thoracic Society (ATS). Aspiro’s CEO and Co-Founder, James Lovgren, […]
Aspiro Therapeutics Named Finalist in Flinn Foundation Bioscience Entrepreneurship Program
Tucson, AZ / March 7, 2025 – Aspiro Therapeutics, a biotechnology company developing next-generation treatments for obstructive lung diseases, has been selected as a finalist in the Flinn Foundation Bioscience Entrepreneurship Program. The program recognizes Arizona-based bioscience startups with high-impact innovations poised to improve human health. Aspiro is focused on advancing disease-modifying therapies for respiratory […]
Aspiro Therapeutics CEO to Attend BIO CEO & Investor Conference 2025
Tucson, Arizona / January 27, 2025 — Aspiro Therapeutics, a pioneering biopharmaceutical company dedicated to developing innovative treatments for obstructive lung diseases, announced that its CEO, James Lovgren, will attend the BIO CEO & Investor Conference 2025. The conference, hosted by the Biotechnology Innovation Organization (BIO), is one of the industry’s premier events, bringing together […]
Aspiro Therapeutics Joins Biotechnology Innovation Organization (BIO)
Tucson, AZ / Jan. 22, 2025–Aspiro Therapeutics, a pioneering biotech company dedicated to developing advanced treatments for obstructive lung diseases, is excited to announce its membership with the Biotechnology Innovation Organization (BIO.org). By joining the world’s largest trade association representing the biotechnology industry, Aspiro reaffirms its commitment to advancing groundbreaking science and fostering collaboration across […]
Aspiro Therapeutics and University of Arizona Awarded Follow-On Funding from the Flinn Foundation
Tucson, AZ / January 13, 2025 – Aspiro Therapeutics, in collaboration with the University of Arizona, is honored to announce it has been awarded follow-on funding through the Flinn Foundation Seed Grants to Promote Translational Research program. This additional $100,000 funding underscores the team’s continued progress in developing innovative therapies for obstructive lung diseases. The follow-on […]
Aspiro Therapeutics to Present at Biotech Showcase™ 2025
Pioneering a Novel Disease-Modifying Therapy for Obstructive Lung Disease San Francisco, CA / Jan. 8 2025—Aspiro Therapeutics, an innovator developing an advanced, disease-modifying therapy that targets obstructive lung diseases, today announced that its CEO, James Lovgren, will present at Seed Showcase™, part of Biotech Showcase 2025. The presentation, “A Novel Therapy to Treat Obstructive […]
Aspiro Therapeutics Acknowledges Co-Founder Dr. Julie Ledford’s Flinn Foundation Seed Grant for Pioneering Research in Respiratory Health
Tucson, AZ / May 1, 2024 – Aspiro Therapeutics proudly highlights the foundational work of co-founder Dr. Julie Ledford, whose research, funded by a Flinn Foundation Seed Grant awarded in June 2023, played a key role in Aspiro’s formation and scientific direction. Awarded through her role at the University of Arizona, Dr. Ledford’s research focuses on […]